Understanding how tumors and immune cells interact in kidney cancer treatment
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
This study is looking at how the immune system responds to kidney cancer and aims to find out why some people do better with certain treatments called immune checkpoint inhibitors, so we can create more tailored treatment plans for patients with kidney cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10888152 on NIH RePORTER |
What this research studies
This research investigates the immune response to kidney cancer, specifically focusing on how immune checkpoint inhibitors (ICIs) can be more effective. It aims to identify the specific tumor and immune characteristics that influence the success of these treatments. By analyzing the tumor microenvironment and the behavior of CD8+ T cells, the study seeks to uncover why some patients benefit from ICIs while others do not. This could lead to more personalized treatment strategies for patients with renal cell carcinoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced renal cell carcinoma who are considering or currently receiving immune checkpoint inhibitor therapy.
Not a fit: Patients with early-stage kidney cancer or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for kidney cancer patients, enhancing the effectiveness of immunotherapy.
How similar studies have performed: Previous research has shown promise in understanding immune responses in other cancers, but this approach is particularly novel for renal cell carcinoma.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Braun, David — Yale University
- Study coordinator: Braun, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.